Emrelis (telisotuzumab vedotin-tllv) / AbbVie - LARVOL DELTA

Profiling membrane antigen expression of select antibody-drug conjugate (ADC) targets in EGFR-altered non-small cell lung cancer treated with osimertinib (AACR 2026) - "In patients with EGFR-altered NSCLC, we identified high expression of ERBB2, MET, and TACSTD2 (TROP2) in both pre- and post-treated samples. This may provide rationale for use of these ADC targets in second-line therapy, such as seen in recent approvals for trastuzumab deruxtecan in ERBB2-mutated, telisotuzumab vedotin in c-MET over-expressing, and datopotamab deruxtecan in EGFR-altered NSCLC. Notably, high MET pre-treatment expression was associated with poor survival outcome and appeared to be associated with post-osimertinib resistance."

ADC • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • ERBB3 • HER-2 • MET • NECTIN4 • TACSTD2

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Non-Squamous EGFR-Wildtype NSCLC in the Phase 2 LUMINOSITY Trial. (PubMed, J Clin Oncol) - P2 | "Teliso-V was associated with durable responses in c-Met protein-overexpressing non-squamous EGFR-wildtype NSCLC, especially in those with high c-Met. AEs were generally manageable."

Journal • Metastases • Monotherapy • P2 data • Fatigue • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Pain • Solid Tumor • EGFR • MET

Telisotuzumab Vedotin-Tllv for Locally Advanced or Metastatic, Non-Squamous Non-Small Cell Lung Cancer (ASCO 2026) - No abstract available

Metastases • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

The impact of immediate prior therapies (Tx) on the safety and efficacy of telisotuzumab vedotin (Teliso-V) in patients (pts) with advanced c-Met protein–overexpressing (OE) non-squamous (NSQ) EGFR wildtype (WT) NSCLC in the phase II LUMINOSITY study (ELCC 2026) - P2 | "Clinical trial identification NCT03539536.Editorial acknowledgement Medical writing support was provided by Joanne Franklin, PhD, CMPP, from Aptitude Health, The Hague, the Netherlands, and funded by AbbVie.Legal entity responsible for the study AbbVie Inc.Funding AbbVie Inc. Table: 34P c-Met OE total Pt (n=22) ICI (n=20) Pt+ICI (n=67) MT–I (n=10) c-Met–I (n=4) ALL (n=127)a ORR, n (%)[95% CI] 9 (40.9)[20.7, 63.6] 11 (55.0)[31.5, 76.9] 13 (19.4)[10.8, 30.9] 4 (40.0)[12.2, 73.8] 2 (50.0)[6.8, 93.2] 39 (30.7)[22.8, 39.5] mPFS, months[95% CI] 5.3[3.0, 8.3] 8.0[3.0, 14.5] 6.7[4.1, 9.6] 11.3[2.7, -] 4.8[3.7, -] 5.9[5.2, 8.3] mOS, months[95% CI] 12.7[3.8, 21.9] 22.9[5.2, 30.3] 14.6[9.0, 17.1] 29.0[7.0, -] 14.7[3.7, -] 14.7[9.9, 17.1] aIncludes 4 pts who received other targeted Tx (different targets [n=3] and pemetrexed [n=1]). -, non-estimable."

Clinical • Metastases • P2 data • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Solid Tumor • EGFR • MET

ANT045: A novel format, antibody fragment drug-conjugate (FDC) product for challenging cMET-expressing solid tumors (AACR 2026) - "ANT-045 demonstrates superior tumor cure efficacy in cMET high, moderate and low CDX and PDX gastric cancer xenograft models and better tolerability compared to the leading competitor ADCs, notably telisotuzumab vedotin. In a non-GLP, non-human primate study, ANT-045 was well tolerated with a predicted half-life in humans of around 12-14 hours supporting a viable clinical dosing strategy with a wide therapeutic window. Insights into how FDCs behave in vivo through quantitative uptake studies and toxicological parameters will be shared and how these have informed our follow-up products."

Gastric Cancer • Oncology • Solid Tumor

LUMINOSITY, a phase 2 study of telisotuzumab vedotin in patients with c-Met protein–overexpressing non-squamous EGFR-wildtype advanced NSCLC: Efficacy outcomes by prior therapy. (ASCO 2025) - P2 | "This analysis demonstrated that Teliso-V elicited durable responses in pts with c-Met protein–OE NSQ EGFR-WT NSCLC regardless of whether they had received prior platinum or platinum + ICI therapies; the efficacy outcomes in these subgroups were consistent with those in the overall pt population. aPer independent central review. DOR, duration of response."

Clinical • IO biomarker • Metastases • P2 data • Fatigue • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Pain • Solid Tumor • EGFR • MET

TeliMET NSCLC-04: A phase 2, open-label, randomized, global study of 2 telisotuzumab vedotin regimens in patients with previously treated c-Met protein–overexpressing, locally advanced/metastatic non-squamous EGFR wildtype non-small cell lung cancer. (ASCO 2025) - P2 | "The primary efficacy endpoint is objective response based on RECIST v1.1 by blinded independent central review (BICR). Secondary endpoints are pharmacokinetics, patient-reported outcomes, duration of response by BICR, progression-free survival by BICR, and overall survival."

Clinical • Metastases • P2 data • Interstitial Lung Disease • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Pain • Pulmonary Disease • Respiratory Diseases • Solid Tumor • EGFR • MET

RC108, a c-Met-targeting ADC, exhibits differential cytotoxicity between cMet-high and HGF-dependent tumor cells compared with Teliso-V, suggesting a potential safety advantage (AACR 2026) - "Importantly, RC108 was associated with low rates of peripheral neuropathy, a markedly lower incidence of interstitial lung disease (ILD), and no observed ocular toxicity. In summary, RC108 is a c-MET-targeted ADC with distinct properties to be recognized in further studies and may have potentially improved safety margin."

ADC • Clinical • Tumor cell • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Quantitative c-MET immunohistochemistry reveals prognostic subgroups in papillary renal cell carcinoma (AACR 2026) - "As c-MET targeted antibody-drug conjugates (e.g., Telisotuzumab vedotin) show therapeutic promise in several cancers, we aimed to quantitatively evaluate c-MET expression in a strictly defined PRCC cohort and to clarify its prognostic value using an image analysis platform. A total of 505 surgically resected PRCC cases (1989-2023, Asan Medical Center) were reclassified according to the 2022 WHO system after excluding non-PRCC entities using a 19-marker IHC panel... This study's strength lies in its large, rigorously reclassified PRCC cohort and the combined use of manual and automated scoring methods. Importantly, automated HALO scoring provided an objective, reproducible measure of c-MET expression while maintaining excellent concordance with manual evaluation, supporting its utility in standardizing biomarker assessment. Although PRCC subtyping is no longer recommended in the current WHO classification, we found that low c-MET expression strongly correlated with..."

Genito-urinary Cancer • Kidney Cancer • Oncology • Papillary Renal Cell Carcinoma • Renal Cell Carcinoma • Solid Tumor • MET

Ex vivo micro-tumor testing platform to guide patient stratification for clinical development of ADCs (AACR 2026) - "This study evaluates ex vivo sensitivity to clinically relevant ADCs in ovarian (OC), non-small cell lung (NSCLC), and colorectal (CRC) cancer, aiming to identify predictive biomarkers and guide patient stratification to optimize clinical benefit.Materials and Methods Ex vivo evaluation of patient specific responses to ADCs was performed by testing mirvetuximab-soravtansine (MIRV) in OC patient samples (N=25), ifinatamab deruxtecan (IFI) in CRC patient samples (N=5) and telisotuzumab vedotin (TEL) in NSCLC patient samples (N=10)...A strong correlation was observed between MIRV and paclitaxel sensitivity (R = 0.86), both of which target tubulin. A reduced correlation was observed for MIRV and carboplatin (R = 0.59), that acts by crosslinking DNA...The platform is future-ready, offering multimodal capabilities including tumor microenvironment (TME) characterization, target protein profiling capturing patient heterogeneity, and assessment of bystander and synergistic..."

ADC • Preclinical • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

EGFR and MET mRNA overexpression in non-small cell lung cancer: Prevalence and sensitivity to targeted therapies (ESMO-TAT 2026) - "MET-overexpressing models were highly sensitive to MET inhibition by tepotinib and capmatinib, with approximately 70% reduction in viability at <0.1 μM concentration, and one model showed sensitivity to the telisotuzumab vedotin, a MET ADC. The EGFR-overexpressing model exhibited strong sensitivity to afatinib and zipalertinib, whereas the anti-EGFR antibody cetuximab induced limited growth inhibition. mRNA overexpression of MET and EGFR identifies a small subset of NSCLC patients which may represent potential candidates for targeted treatment. mRNA overexpression of MET and EGFR identifies a small subset of NSCLC patients which may represent potential candidates for targeted treatment. Patient-derived 3D cultures confirmed that MET-overexpressing models are sensitive to MET inhibitors and to telisotuzumab-vedotin, while EGFR-overexpressing models show sensitivity to EGFR TKIs and limited response to the anti-EGFR antibody cetuximab. These findings support the..."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

The Impact of Preanalytical Variables on c-MET, HER2, and PD-L1 Immunohistochemistry in Non-Small Cell Lung Carcinoma Cytological Specimens (USCAP 2026) - "Current guidelines require predictive IHC testing in NSCLC patients to identify patients who are eligible for fam-trastuzumab deruxtecan-nxki (HER2 IHC3+), telisotuzumab vedotin (c-MET IHC3+), and/or checkpoint inhibitor therapy (PD-L1 TPS+). Our study highlights the need for optimizing preanalytical variables in cytology specimen processing, even when testing FFPE CBs, to ensure the reliability of predictive IHC results that guide therapeutic decisions."

IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2 • MET

The Impact of Preanalytical Variables on c-MET, HER2, and PD-L1 Immunohistochemistry in Non-Small Cell Lung Carcinoma Cytological Specimens (USCAP 2026) - "Current guidelines require predictive IHC testing in NSCLC patients to identify patients who are eligible for fam-trastuzumab deruxtecan-nxki (HER2 IHC3+), telisotuzumab vedotin (c-MET IHC3+), and/or checkpoint inhibitor therapy (PD-L1 TPS+). Our study highlights the need for optimizing preanalytical variables in cytology specimen processing, even when testing FFPE CBs, to ensure the reliability of predictive IHC results that guide therapeutic decisions."

IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2 • MET

Comparative Efficacy and Safety of Telisotuzumab Vedotin in C-Met-Positive Advanced Non- Small Cell Lung Cancer: A Systematic Review and Meta-Analysis (ATS 2026) - No abstract available

Metastases • Retrospective data • Review • Lung Cancer • Oncology • Solid Tumor • MET

LUMINOSITY: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=270 | Active, not recruiting | Sponsor: AbbVie | Trial primary completion date: Jul 2026 ➔ Oct 2025

Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

LUMINOSITY: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=270 | Active, not recruiting | Sponsor: AbbVie | Trial completion date: Oct 2025 ➔ Aug 2026 | Trial primary completion date: Oct 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

LUMINOSITY: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=270 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Enrollment closed • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

LUMINOSITY: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=270 | Recruiting | Sponsor: AbbVie | Trial primary completion date: Jan 2025 ➔ Sep 2025

Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

LUMINOSITY: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=310 | Recruiting | Sponsor: AbbVie | Trial completion date: Jan 2025 ➔ Sep 2025

Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

LUMINOSITY: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=310 | Recruiting | Sponsor: AbbVie | N=233 ➔ 310

Enrollment change • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

LUMINOSITY: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=310 | Not yet recruiting | Sponsor: AbbVie

New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

LUMINOSITY: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=310 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • EGFR • MET

LUMINOSITY: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=310 | Recruiting | Sponsor: AbbVie | Trial completion date: Dec 2021 ➔ Oct 2023

Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • EGFR • MET

LUMINOSITY: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=310 | Recruiting | Sponsor: AbbVie | Trial completion date: Aug 2023 ➔ Jan 2025 | Trial primary completion date: Oct 2021 ➔ Jan 2025

Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

LUMINOSITY: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=310 | Recruiting | Sponsor: AbbVie | Trial completion date: May 2024 ➔ Aug 2023

Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • EGFR • MET